您的位置: 首页 > 2018年11月 第49卷 第6期 > 文字全文
2023年7月 第38卷 第7期11
目录

新辅助化疗联合保肢手术治疗四肢骨肉瘤的临床研究

Neoadjuvant chemotherapy combined with limb salvage surgery for the treatment of limb osteosarcoma

来源期刊: 广州医药 | 75-78 发布时间:2021-11-30 收稿时间:2025/11/13 17:17:20 阅读量:27
作者:
关键词:
骨肉瘤保肢手术、新辅助化疗
OsteosarcomaLimb salvage operationNeoadjuvant chemotherapy
DOI:
10.3969/j.issn.1000-8535.2018.06.017
收稿时间:
2018-05-15 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 研究新辅助化疗联合保肢手术治疗骨肉瘤的临床效果。方法 根据既往治疗骨肉瘤方法的不同,将56例患者分为对传统保肢组(A组)和现代保肢组(B组),各28例。A组用采用传统保肢方案,即保肢手术+术后化疗方案进行;B组采用现代保肢方案,即新辅助化疗+保肢手术+术后化疗方案进行。化疗方案均采用CTX + VCR +MTX+ ADM方案,比较两组转移/复发率、术后1 年、2年及 3 年生存率、肢体功能、临床疗效情况。结果 比较两组的转移/复发率及3年后的死亡率,B组低于A组(P<0.05);肢体功能优良率及临床疗效,B组高于A组(P<0.05)。结论 新辅助化疗联合保肢手术能够降低骨肉瘤患者转移/复发率、死亡率,改善肢体功能,提高临床疗效。
Objective To study the clinical effect of neoadjuvant chemotherapy combined with limb salvage surgery for osteosarcoma. Methods Based on the previous methods of treating osteosarcoma, 56 patients were divided into the traditional limb salvage group (A group) and the modern limb salvage group (B group), 28 cases for each. The traditional limb salvage surgery + postoperative chemotherapy regimen were used in group A, and modern limb salvage regimen was performed in group B, ie neoadjuvant chemotherapy + limb salvage surgery + postoperative chemotherapy. The CTX + VCR +MTX+ ADM protocol was used in the chemotherapy regimens. The metastasis/recurrence rate, the 1-year, 2-year and 3-year survival rates, limb function, and clinical efficacy were compared between the two groups. Results The metastasis/recurrence rate and the mortality rate after 3 years in the two groups were compared. The B group was lower than that of the group A (P<0.05). The excellent rate of limb function and clinical efficacy were higher in the B group than that of in the group A (P<0.05). Conclusion Neoadjuvant chemotherapy combined with limb salvage surgery may reduce the metastasis/recurrence rate and mortality of osteosarcoma patients, improve limb function and increase clinical efficacy.
1、 黄飞,王显勋,罗小江.新辅助化疗结合保肢手术治疗骨肉瘤的临床研究[J].现代肿瘤医学,2015,23(13):1911-1913. 黄飞,王显勋,罗小江.新辅助化疗结合保肢手术治疗骨肉瘤的临床研究[J].现代肿瘤医学,2015,23(13):1911-1913.
2、 徐明,许宋锋,于秀淳.骨肉瘤不含大剂量甲氨蝶呤新辅助化疗的疗效观察[J]. 中华肿瘤防治杂志,2015,22(2):138-142. 徐明,许宋锋,于秀淳.骨肉瘤不含大剂量甲氨蝶呤新辅助化疗的疗效观察[J]. 中华肿瘤防治杂志,2015,22(2):138-142.
3、 张利恒,李亮,李晓峰,等.骨肉瘤化疗药物敏感性实验研究[J].中国实验诊断学,2013,17(1):100-102. 张利恒,李亮,李晓峰,等.骨肉瘤化疗药物敏感性实验研究[J].中国实验诊断学,2013,17(1):100-102.
4、 YANCEY A,HARRIS M S,EGBELAKIN A,et al.Risk factorsfor cisplatin associated ototoxicity in pediatric oncology patients[J]. Pediatr Blood Cancer,2012,59(1):144-148. YANCEY A,HARRIS M S,EGBELAKIN A,et al.Risk factorsfor cisplatin associated ototoxicity in pediatric oncology patients[J]. Pediatr Blood Cancer,2012,59(1):144-148.
5、 陈丰,郭智,瞿嵘 .大剂量异环磷酰胺联合脂质体阿霉素治疗骨肉瘤的临床研究[J]. 实用癌症杂志,2015,30(5):676-678. 陈丰,郭智,瞿嵘 .大剂量异环磷酰胺联合脂质体阿霉素治疗骨肉瘤的临床研究[J]. 实用癌症杂志,2015,30(5):676-678.
6、 BERNTHAL N M,FEDERMAN N,EILBER F R,et al.Longterm results( >25 Years)of a randomized,prospective clinicaltrial evaluating chemotherapy in patients with high-grade,operable osteosarcoma[J]. Cancer,2012,118(23):5888-5893. BERNTHAL N M,FEDERMAN N,EILBER F R,et al.Longterm results( >25 Years)of a randomized,prospective clinicaltrial evaluating chemotherapy in patients with high-grade,operable osteosarcoma[J]. Cancer,2012,118(23):5888-5893.
7、 LEE J A,PAIK E K,SEO J,et al.Radiotherapy and gemcitabine docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma[J]. J Clin Oncol,2016,46(2):138-143. LEE J A,PAIK E K,SEO J,et al.Radiotherapy and gemcitabine docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma[J]. J Clin Oncol,2016,46(2):138-143.
8、 LO SCHIAVO A,RUOCCO E,RUSSO T,et al.Locus minoris resistentiae:An old but still valid way of thinking in medicine[J].Clin Dermatol,2014,32(5): 553-556. LO SCHIAVO A,RUOCCO E,RUSSO T,et al.Locus minoris resistentiae:An old but still valid way of thinking in medicine[J].Clin Dermatol,2014,32(5): 553-556.
9、 MARDEKIAN S K,TULUC M.Malignant sarcomatous transformation of fibrous dysplasia[J].Head Neck Pathol,2015,9(1):100-103. MARDEKIAN S K,TULUC M.Malignant sarcomatous transformation of fibrous dysplasia[J].Head Neck Pathol,2015,9(1):100-103.
10、 黄成校,郭卫春,郭哲.骨肉瘤的治疗进展[J].医学综述,2013,19( 11): 1979-1982. 黄成校,郭卫春,郭哲.骨肉瘤的治疗进展[J].医学综述,2013,19( 11): 1979-1982.
11、 牛晓辉,徐海荣.骨肉瘤的化疗进展[J].中国癌症志,2012,22(9):663-668. 牛晓辉,徐海荣.骨肉瘤的化疗进展[J].中国癌症志,2012,22(9):663-668.
12、 徐建立,张林,徐万鹏.骨肉瘤COSS–96方案综合治疗效果分析[J].中华肿瘤防治杂志,2013,20(8):622-624. 徐建立,张林,徐万鹏.骨肉瘤COSS–96方案综合治疗效果分析[J].中华肿瘤防治杂志,2013,20(8):622-624.
13、 肖兢,喻紫晨.肢体骨肉瘤合并病理性骨折的临床特点及相关影响因素[J].实用癌症杂志,2014,29(3):346-348. 肖兢,喻紫晨.肢体骨肉瘤合并病理性骨折的临床特点及相关影响因素[J].实用癌症杂志,2014,29(3):346-348.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录